Dr. Jamieson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 W Arbor Dr
San Diego, CA 92103Phone+1 858-822-6276Fax+1 858-822-6288
Education & Training
- Stanford Health CareFellowship, Blood & Bone Marrow Transplant, 1999 - 2002
- University of British ColumbiaClass of 1995
Certifications & Licensure
- CA State Medical License 1999 - 2026
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Top Doctors:San Diego Area Castle Connolly, 2013
- Top Doctors:Southern California Castle Connolly, 2012
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
- Join now to see all
Clinical Trials
- Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF Start of enrollment: 2011 Jun 01
- A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
- UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia Start of enrollment: 2014 Aug 08
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsClinical Trial to Assess the Safety and Tolerability of Anti-IL 23 Monoclonal Antibody Guselkumab in Patients With Alcohol-Associated Liver Disease.Luis Antonio Diaz, Sheldon Morris, Shravan Dave, Susy M Kim, Wathnita Sarik
Alimentary Pharmacology & Therapeutics. 2025-04-01 - Impact of Recent Translational and Therapeutic Developments on Clinical Course of BCR::ABL1-Positive and -Negative Myeloproliferative Neoplasms.Tariq I Mughal, John Mascarenhas, Raajit K Rampal, Prithviraj Bose, Thomas Lion
Hematological Oncology. 2025-01-01 - 2 citationsLong-term clinical and safety outcomes from a single-site phase 1 study of neural stem cell transplantation for chronic thoracic spinal cord injury.Joel R Martin, Daniel Cleary, Mickey E Abraham, Michelle Mendoza, Betty Cabrera
Cell Reports. Medicine. 2024-12-17
Abstracts/Posters
- Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...Catriona Jamieson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...Catriona Jamieson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary MyelofibrosisCatriona Jamieson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Inflammatory Cytokine Responsive Enzymatic Mutagenesis Fuels Myeloproliferative Neoplasm Pre-Leukemia Stem Cell Evolution61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- RNA Modifications in Hematologic Malignancies60th American Society of Hematology Annual Meeting - 12/2/2018
- RNA Modifications in Hematology60th American Society of Hematology Annual Meeting - 12/1/2018
- Join now to see all
Press Mentions
- Targeting Therapy-Resistant Pediatric Acute Myeloid LeukemiaMarch 8th, 2023
- UC San Diego’s Astrobiotechnology Hub to Drive Drug Discovery in SpaceFebruary 28th, 2023
- Small Molecule Drug Reverses ADAR1-Induced Cancer Stem Cell Cloning CapacityFebruary 16th, 2023
- Join now to see all
Grant Support
- Exploring the Impact of Base Deaminase Deregulation on Precancer EvolutionUNIVERSITY OF CALIFORNIA, SAN DIEGO2024–2029
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: